MarketCap
Facebook
X
Telegram
Idera Pharmaceuticals EBITDA | IDRA
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Idera Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -27.7 M | -27.6 M | -36.6 M | -46 M | -60.6 M | -65.8 M | -38.2 M | -48.3 M | -38.6 M | -18 M | -19.6 M | -25.4 M | -17.4 M | 7.95 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.95 M | -65.8 M | -33 M |
Quarterly EBITDA Idera Pharmaceuticals
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -20.6 M | - | -9.32 M | -5.36 M | -4.18 M | - | -5.95 M | -7.55 M | -9.93 M | - | -7.43 M | -7.97 M | -13.1 M | - | -11.3 M | -11.4 M | -11.2 M | - | -11.8 M | -16.2 M | -20.1 M | - | -14.5 M | -21.4 M | -15 M | - | -12.8 M | -13.4 M | -12.8 M | - | -11.3 M | -12.7 M | -12.4 M | - | -9.46 M | -8.28 M | -8.94 M | - | -4.65 M | -3.53 M | -3.81 M | - | -4.7 M | -5.26 M | -5.41 M | - | -5.14 M | -6.02 M | -6.7 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.53 M | -21.4 M | -10 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Eiger BioPharmaceuticals
EIGR
|
-71.5 M | - | -9.21 % | $ 2.55 M |  USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
BELLUS Health
BLU
|
-77.9 M | - | - | $ 2.47 B |  Canada |
 |
bluebird bio
BLUE
|
-210 M | - | - | $ 546 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
-116 M | - | - | $ 13.6 B | USA |
 |
IGM Biosciences
IGMS
|
-199 M | - | - | $ 76.9 M | USA |
 |
Marinus Pharmaceuticals
MRNS
|
-131 M | - | - | $ 29.6 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
-2.04 M | - | - | $ 216 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-32.8 M | - | - | $ 35.4 M | USA |
 |
ContraFect Corporation
CFRX
|
-64.5 M | - | -5.16 % | $ 5.39 M | USA |
 |
Sigilon Therapeutics
SGTX
|
-42.4 M | - | - | $ 728 M | USA |
 |
Rubius Therapeutics
RUBY
|
-172 M | - | -33.55 % | $ 7.81 M | USA |
 |
Aptinyx
APTX
|
-62.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
TRACON Pharmaceuticals
TCON
|
-9.26 M | - | -1.38 % | $ 46.8 M | USA |
 |
Mirati Therapeutics
MRTX
|
-757 M | - | - | $ 3.3 B | USA |
 |
Revance Therapeutics
RVNC
|
-305 M | - | - | $ 309 M | USA |
 |
Allogene Therapeutics
ALLO
|
-197 M | $ 0.93 | -11.99 % | $ 205 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
-10.6 M | - | -37.48 % | $ 476 K | USA |
 |
Epizyme
EPZM
|
-233 M | - | - | $ 249 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | USA |
 |
ORIC Pharmaceuticals
ORIC
|
-142 M | $ 8.9 | -3.63 % | $ 781 M | USA |
 |
Forward Pharma A/S
FWP
|
-3.87 M | - | -0.75 % | $ 18.7 M |  Danmark |
 |
Orchard Therapeutics plc
ORTX
|
-124 M | - | 1.02 % | $ 90.8 M |  Britain |
 |
La Jolla Pharmaceutical Company
LJPC
|
21.9 M | - | - | $ 154 M | USA |
 |
Oyster Point Pharma
OYST
|
-96.5 M | - | - | $ 300 M | USA |
 |
Nabriva Therapeutics plc
NBRV
|
-55.3 M | - | - | $ 4.55 M |  Irlanda |
 |
Intercept Pharmaceuticals
ICPT
|
-18.3 M | - | - | $ 643 M | USA |
 |
NGM Biopharmaceuticals
NGM
|
-149 M | - | - | $ 127 M | USA |
 |
Regulus Therapeutics
RGLS
|
-49.7 M | - | - | $ 155 M | USA |
 |
9 Meters Biopharma
NMTR
|
-42 M | - | -42.97 % | $ 1.05 M | USA |
 |
Chinook Therapeutics
KDNY
|
-182 M | - | - | $ 2.6 B | USA |
 |
Lumos Pharma
LUMO
|
-36.6 M | - | - | $ 35.3 M | USA |
 |
Syros Pharmaceuticals
SYRS
|
-127 M | - | -8.44 % | $ 3.4 M | USA |
 |
NanoViricides
NNVC
|
-7.79 M | $ 1.44 | 8.27 % | $ 29.1 M | USA |
 |
Gamida Cell Ltd.
GMDA
|
-62.7 M | - | -18.25 % | $ 5.04 M |  Israel |
 |
GT Biopharma
GTBP
|
-12.4 M | $ 3.99 | -7.64 % | $ 22 M | USA |
 |
Aravive
ARAV
|
-70 M | - | -13.39 % | $ 1.45 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | USA |
 |
BioLineRx Ltd.
BLRX
|
-10.3 M | $ 1.52 | -3.8 % | $ 3.75 B | Israel |
 |
VistaGen Therapeutics
VTGN
|
-71.9 M | $ 0.18 | -0.46 % | $ 6.85 M | USA |
 |
C4 Therapeutics
CCCC
|
-113 M | $ 3.0 | -4.76 % | $ 249 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 1.67 | -0.6 % | $ 2.75 M | Israel |
 |
Cytokinetics, Incorporated
CYTK
|
-602 M | $ 56.2 | 1.92 % | $ 6.75 M | USA |
 |
Curis
CRIS
|
-5.54 M | $ 0.66 | -5.68 % | $ 8.69 M | USA |
 |
Exelixis
EXEL
|
901 M | $ 71.0 | -1.04 % | $ 19.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | USA |
 |
Amgen
AMGN
|
14.2 B | $ 465.26 | 0.01 % | $ 250 B | USA |
 |
Biogen
BIIB
|
780 M | $ 253.37 | -0.59 % | $ 37.1 B | USA |
 |
Edesa Biotech
EDSA
|
-7.79 M | $ 2.01 | -19.28 % | $ 11.4 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-679 M | $ 15.12 | -0.72 % | $ 978 M | USA |